Given that NAT10 inhibition resulted in the downregulation of ERRFI1, which could reactivate EGFR signaling in CRC cells, we further evaluated whether the EGFR-specific monoclonal antibody cetuximab can inhibit the reactivation of EGFR signaling and improve the therapeutic efficacy of Remodelin in KRAS wild-type CRC cells. This evidence concerns the gene NAT10 and colorectal carcinoma.